UCD

Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

Retrieved on: 
水曜日, 5月 8, 2024
Corporation, FDA, Society, EAP, Sale, Celiprolol, Acer, Investment, Priority review, NDA, Conference call, Research, Sleep, License, Conference, Discover, Idiopathic hypersomnia, Disease, Exercise, IH, PDUFA, Patient, Acquisition, Physician, NPC, UCD, Caregiver, Therapy, Pharmaceutical industry

CELEBRATION, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the first quarter ended March 31, 2024. 

Key Points: 
  • ET
    CELEBRATION, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the first quarter ended March 31, 2024.
  • Zevra has seen a meaningful increase in reimbursement coverage, reaching nearly 75% of covered lives as of May 1, 2024.
  • Overview of Q1 2024 Financial Results:
    Net revenue for Q1 2024 was $3.4 million, compared to net revenue of $3.2 million in Q1 2023.
  • ET, to discuss its corporate and financial results for Q1 2024.

SmallRig Leads the Future of Imaging with 2024 Global Forum and Inaugural Top 10 Scene List

Retrieved on: 
金曜日, 4月 12, 2024
Vivo, Panasonic, Sigma, DJI, RED, Lighting, Nikon, UCD, Customer, Video game

SHENZHEN, China, April 12, 2024 /PRNewswire/ -- The SmallRig brand launch conference and the 2024 Global Imaging Scene Industry Forum, jointly organized by CBNData and SmallRig, were recently held in Shenzhen. The event attracted over 300 participants, including SmallRig users worldwide, top management executives from global imaging leaders, among them, Sony, Canon, RED, Sigma and vivo. During the event, SmallRig founder Zhou Yang took the stage to reveal the company's new strategic direction and brand identity.

Key Points: 
  • SHENZHEN, China, April 12, 2024 /PRNewswire/ -- The SmallRig brand launch conference and the 2024 Global Imaging Scene Industry Forum, jointly organized by CBNData and SmallRig, were recently held in Shenzhen.
  • The event attracted over 300 participants, including SmallRig users worldwide, top management executives from global imaging leaders, among them, Sony, Canon, RED, Sigma and vivo.
  • During the event, SmallRig founder Zhou Yang took the stage to reveal the company's new strategic direction and brand identity.
  • Leveraging insights from its 4 million users worldwide, SmallRig, in collaboration with CBNData, identified the top 10 global imaging scenes and three keywords for 2024.

SmallRig Leads the Future of Imaging with 2024 Global Forum and Inaugural Top 10 Scene List

Retrieved on: 
金曜日, 4月 12, 2024
Vivo, Panasonic, Sigma, DJI, RED, Lighting, Nikon, UCD, Customer, Multimedia, Video game

SHENZHEN, China, April 12, 2024 /PRNewswire/ -- The SmallRig brand launch conference and the 2024 Global Imaging Scene Industry Forum, jointly organized by CBNData and SmallRig, were recently held in Shenzhen. The event attracted over 300 participants, including SmallRig users worldwide, top management executives from global imaging leaders, among them, Sony, Canon, RED, Sigma and vivo. During the event, SmallRig founder Zhou Yang took the stage to reveal the company's new strategic direction and brand identity.

Key Points: 
  • SHENZHEN, China, April 12, 2024 /PRNewswire/ -- The SmallRig brand launch conference and the 2024 Global Imaging Scene Industry Forum, jointly organized by CBNData and SmallRig, were recently held in Shenzhen.
  • The event attracted over 300 participants, including SmallRig users worldwide, top management executives from global imaging leaders, among them, Sony, Canon, RED, Sigma and vivo.
  • During the event, SmallRig founder Zhou Yang took the stage to reveal the company's new strategic direction and brand identity.
  • Leveraging insights from its 4 million users worldwide, SmallRig, in collaboration with CBNData, identified the top 10 global imaging scenes and three keywords for 2024.

Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

Retrieved on: 
木曜日, 3月 28, 2024
Narcolepsy, Exercise, Somnolence, New Drug Application, Patient, Visual analogue scale, Sale, NDA, G&A, Arimoclomol, Nature, IND, Bank statement, Microsoft Access, Investment, Therapy, Priority review, Corporation, Audit committee, Research, Niemann–Pick disease, Medical science liaison, Sleep disorder, Brain, Trial of the century, Safety, Interim, Food, Sleep, QuickStart, Disease, FY, Acquisition, Emetine, UCD, COL3A1, Celiprolol, Syndrome, FDA, Marketing, Conference call, Conference, EAP, SDX, NPC, Epworth Sleepiness Scale, Idiopathic hypersomnia, Physician, PDUFA, Pharmaceutical industry

CELEBRATION, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the fourth quarter and year ended December 31, 2023. 

Key Points: 
  • ET
    CELEBRATION, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the fourth quarter and year ended December 31, 2023.
  • “We made solid progress on our key priorities in 2023,” said Neil F. McFarlane, President and Chief Executive Officer of Zevra.
  • Overview of Q4 2023 and FY 2023 Financial Results:
    Net revenue for Q4 2023 was $13.2 million, compared to prior year Q4 net revenue of $2.2 million.
  • ET, to discuss its corporate and financial results for Q4 and FY 2023.

CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders

Retrieved on: 
木曜日, 3月 21, 2024
Disability, Gene, Enzyme, Seizure, Patient, DSM-IV codes, RNA, Messenger, Protein, Trial of the century, CPS1, UCD, Clinical trial, Therapy, Safety, Pharmacokinetics, Ammonia, Brain damage, Disorder, Blood, Pharmaceutical industry

“Most importantly, the clinical development of CMP-CPS-001 is a step toward potentially bringing a new, disease-modifying treatment to individuals living with UCDs.

Key Points: 
  • “Most importantly, the clinical development of CMP-CPS-001 is a step toward potentially bringing a new, disease-modifying treatment to individuals living with UCDs.
  • People with urea cycle disorders accumulate excessive ammonia in their blood, which may cause irreversible brain damage, disability, and seizures, and may be fatal.
  • CMP-CPS-001 targets carbamoyl phosphate synthetase 1 (CPS1), a key enzyme that catalyzes the first step of the urea cycle.
  • For more information about the Phase 1 clinical study of CMP-CPS-001, please visit clinicaltrials.gov ( NCT06247670 ).

UCD Smurfit School appoints David McCourt as Adjunct Professor to support leadership in Artificial Intelligence

Retrieved on: 
水曜日, 3月 20, 2024
Marriage, United, Public policy, United Nations, Policy, Child, Entrepreneurship, AI, Private sector, Student, Leg, UCD, McCourt, System, Economist, Digital technology, Telecommunications, Artificial intelligence, National broadband plan, School, Management

DUBLIN, March 20, 2024 /PRNewswire/ -- UCD Michael Smurfit Graduate Business School has announced that technology, media, and telecommunications entrepreneur David McCourt has been appointed as an Adjunct Full Professor to support the School's national and global leadership ambitions in Artificial Intelligence.

Key Points: 
  • DUBLIN, March 20, 2024 /PRNewswire/ -- UCD Michael Smurfit Graduate Business School has announced that technology, media, and telecommunications entrepreneur David McCourt has been appointed as an Adjunct Full Professor to support the School's national and global leadership ambitions in Artificial Intelligence.
  • As founder and CEO of worldwide investment firm Granahan McCourt Capital and the Chairman of National Broadband Ireland, McCourt is described by The Economist as possessing "impeccable credentials as a telecom revolutionary".
  • As Adjunct Professor, McCourt will deliver a number of lectures on AI, technology, entrepreneurship, and leadership to students across all levels and will also provide guidance in programme development, thought leadership and industry engagement.
  • Commenting on his appointment, David McCourt added, "It is an honor to join UCD as an Adjunct Professor and I am especially pleased to contribute to the School's vision for AI.

Pheburane® (sodium phenylbutyrate) is now on the Medicaid Preferred Drug List in 10 states

Retrieved on: 
火曜日, 1月 23, 2024
Patient, Government, Medicaid, Ammonia, Digestion, Health, Standard of care, Pharmacy, DSM-IV codes, DPG, Blood, UCD, Appetite, Pharmaceutical industry

Pheburane® is the safe, effective and palatable adjunctive therapy to the standard of care, which includes dietary management, for the treatment of certain UCDs.

Key Points: 
  • Pheburane® is the safe, effective and palatable adjunctive therapy to the standard of care, which includes dietary management, for the treatment of certain UCDs.
  • With the continued favorable commercial and Medicaid coverage updates, Pheburane® is reaching more patients all over the USA while being recognized as a first-line therapy by health authorities in key states.
  • UCDs are rare, chronic, genetic conditions that can be fatal if left untreated, and can impact children from the time of birth.
  • UNIK Support offers specialized services including a copay savings program, patient care liaison services, mail order pharmacy and other support services.

Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

Retrieved on: 
木曜日, 12月 7, 2023
Liver, UDCA, Chapter Two, Woman, FDA, MAA, Fatigue, Nausea, Primary biliary cholangitis, Inflammation, ADR, Patent, Liver disease, Diagnosis, AMF, CHMP, Ascending cholangitis, UCD, Business, ACLF, PDUFA, Itch, Risk, New Drug Application, OA, Common, EASL, MASH, Liver failure, Safety, Ammonia, Elafibranor, Therapy, Epidemiology, History, Patient, Cholangiocarcinoma, Food, Health care, EMA, Ursodeoxycholic acid, MHRA, Cirrhosis, Medicine, NTZ, EVP, Cholestasis, NASH, Research, Diarrhea, Bile, NDA, PBC, Abdominal pain, Clinical trial, European Medicines Agency, IPN, PPAR, P10, CCA, Fibrosis, Pharmaceutical industry

An oral, once-daily dual peroxisome activated receptor alpha/delta (PPAR α,δ) agonist, investigational elafibranor could potentially be the first novel second-line treatment for the rare, cholestatic liver disease, PBC, in nearly a decade.

Key Points: 
  • An oral, once-daily dual peroxisome activated receptor alpha/delta (PPAR α,δ) agonist, investigational elafibranor could potentially be the first novel second-line treatment for the rare, cholestatic liver disease, PBC, in nearly a decade.
  • The trial enrolled 161 patients who were randomized 2:1 to receive either elafibranor 80mg once daily or placebo.
  • ELATIVE also investigated the effect of treatment with elafibranor on pruritus (severe itch), a significant symptom burden amongst people living with PBC.
  • Findings from the secondary endpoint using the PBC Worst Itch NRS score, showed a reduction in pruritis for elafibranor, which was not statistically significant.

Taoglas Shoots for the Stars in Ireland's First Satellite

Retrieved on: 
月曜日, 12月 4, 2023
Aerospace, IOT (Internet of Things), Manufacturing, Satellite, Technology, CubeSat, European Space Agency, Internet of things, Engineering, RF, GPS, Shock, University College Dublin, Space research, Student, Education, Multimedia, GNSS, Orbit, SpaceX, SpaceX launch vehicles, UCD, Communications satellite, Surveying

Taoglas' GPS/GALILEO patch antenna was chosen for its lightweight and low-volume characteristics while ensuring high gain and wide bandwidth.

Key Points: 
  • Taoglas' GPS/GALILEO patch antenna was chosen for its lightweight and low-volume characteristics while ensuring high gain and wide bandwidth.
  • "We are immensely proud that Ireland's first satellite, EIRSAT-1, will have an Irish satellite antenna and cable solution on board.
  • Taoglas provided the ideal solution with their direct solder mount GNSS antenna, demonstrating the innovation and precision necessary for this pioneering mission."
  • You can watch Taoglas’ video about their involvement in the EIRSAT-1 mission here: https://youtu.be/fr3ZtYtXT0g

Pheburane® (sodium phenylbutyrate) coverage to reach ~80% of commercially insured US patients by January 1st, 2024

Retrieved on: 
木曜日, 10月 26, 2023
Government, Ammonia, History, Courage, Digestion, OTC, UCD, Health, DSM-IV codes, UCD School of Medicine, CPS, Disease, Pharmacy, Medicaid, Sodium phenylbutyrate, Patient, Government of Canada, Appetite, Pharmaceutical industry

Pheburane® is not indicated for the treatment of acute hyperammonemia which can be life-threatening and requires emergency medical treatment.

Key Points: 
  • Pheburane® is not indicated for the treatment of acute hyperammonemia which can be life-threatening and requires emergency medical treatment.
  • UCDs are rare, chronic, genetic conditions that can be fatal if left untreated, and can impact children from the time of birth.
  • It does not require any mixing or oral syringes and there is no weight restriction for patients.
  • UNIK Support offers specialized services including a copay savings program, patient care liaison services, mail order pharmacy and other support services.